Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 494.50% and ...
Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks ...
Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...
WISH-TV on MSN6h
Taco Bell reupping its value menu gameTaco Bell is re-upping its value menu game with the introduction of $5, $7 and $9 luxe cravings boxes, while TikTok is ...
New findings on semaglutide and tirzepatide published in 2024 revealed that the medications may have benefits beyond lowering glucose levels and body weight.At the Cardiometabolic Health Congress in ...
The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.
Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...
Key Takeaways Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback